Impact BioMedical financials
$5.61−1.41%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $32.0K | $0.00 |
| Gross profit | -$392.0K | $0.00 |
| Gross margin | −1225.0% | — |
| Operating income | -$4.3M | -$28.8M |
| Net income | -$11.8M | -$24.7M |
| Net margin | −36993.8% | — |
| Diluted EPS | $-4.80 | $-29.03 |
| EBITDA | -$3.1M | -$2.3M |
| Operating cash flow | -$1.9M | -$2.9M |
| Free cash flow | -$1.9M | -$2.9M |
| Diluted shares | 2.5M | 0.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $3.0K | $2.0M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $8.9M |
| Total assets | $17.4M | $20.3M |
| Total liabilities | $1.9M | $13.1M |
| Shareholders' equity | $15.6M | $7.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology